Alerta

DNA Aptamer Specifically Binding to Envelope Protein of SARS-CoV-2 and Uses Thereof

Absstract of: KR20250106684A

본 발명은 SARS-CoV-2의 외피 단백질에 특이적으로 결합하는 DNA 앱타머 및 이의 용도에 관한 것으로, 구체적으로 본 발명은 SARS-CoV-2 바이러스의 외피 단백질(envelope protein)에 특이적으로 결합하는 DNA 앱타머, 상기 DNA 앱타머를 유효성분으로 포함하는 SARS-CoV-2 바이러스의 외피 단백질(envelope protein) 검출용 조성물, SARS-CoV-2 바이러스 검출용 키트, SARS-CoV-2 바이러스 검출용 칩 또는 마이크로어레이 및 상기 DNA 앱타머를 이용한 SARS-CoV-2 바이러스의 외피 단백질 검출 방법에 관한 것이다. 또한 본 발명은 본 발명의 DNA 앱타머를 유효성분으로 포함하는, 코로나바이러스 감염증-19 진단용 조성물, 코로나바이러스 감염증-19의 예방 또는 치료용 약학적 조성물, SARS-CoV-2 바이러스의 외피 단백질에 특이적 결합하는 DNA 앱타머의 제조방법 및 코로나바이러스 감염증-19의 진단에 필요한 정보를 제공하는 방법에 관한 것이다.

IMPROVED FORMULATION PROVIDING INCREASED STABILITY FOR VACCINES COMPOSITION

Absstract of: WO2025147639A1

The disclosure is directed to a novel liquid vaccine formulation and composition. In one embodiment the novel liquid vaccine formulation comprises an immunogen such as PIV5, a stabilizing agent, and a buffer, with the resulting liquid vaccine formulation maintaining storage-stable immunogenicity with a potency loss of less than 0.5 Log10 at 4°C for at least 4 months. In yet another embodiment the PIV5 immunogen expresses the SARS-CoV-2 S or N protein.

OC43 A A pharmaceutical composition for preventing or treating infection of human coronavirus OC43 or influenza A virus comprising a recombinant bacteriophage

Absstract of: KR20250106189A

재조합 M13 박테리오 파지 YSY184, 재조합 M13 박테리오 파지 YSY184GPP, 재조합 M13 박테리오 파지 YSY184PHH 또는 재조합 M13 박테리오 파지 YSY184SDKP를 포함하는 인간 코로나바이러스 OC43 또는 인플루엔자 A 바이러스 감염증 예방 또는 치료용 약학 조성물에 관한 것이다. 본 발명에 따른 약학 조성물은 인간 코로나바이러스 OC43 또는 인플루엔자 A 바이러스 감염의 저해 효과가 있으며, 종양 괴사 인자-α(TNF-α) 및 인터류킨-6 (IL-6)의 발현을 감소시킨다.

COMPOSITIONS AND METHODS FOR DETECTING SARS-COV -2 NUCLEIC ACID

Absstract of: EP4582563A2

There is described a composition or kit for determining the presence or absence of SARS-CoV-2 in a sample, said composition or kit comprising: (a) a first amplification oligomer combination comprising first and second SARS-CoV-2 region 1-specific amplification oligomers capable of amplifying a first target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2 region 1-specific amplification oligomer comprises a first SARS-CoV-2 region 1-specific target-hybridizing sequence that is from 18 to 27 contiguous nucleotides in length, is contained within SEQ ID NO:26, and contains a nucleotide sequence differing by no more than 0, 1, 2, 3, 4, or 5 nucleotides from the nucleotide sequence of SEQ ID NO:27 or SEQ ID NO:28, and (ii) wherein the second SARS-CoV-2 region 1-specific amplification oligomer comprises a second SARS-CoV-2 region 1-specific target-hybridizing sequence that is from 18 to 23 contiguous nucleotides in length, is contained within SEQ ID NO:85, and contains a nucleotide sequence differing by no more than 0, 1, 2, 3, 4, or 5 nucleotides from the nucleotide sequence of SEQ ID NO:86, SEQ ID NO:87, or SEQ ID NO:88, or (b) a second amplification oligomer combination comprising first and second SARS-CoV-2 region 2-specific amplification oligomers capable of amplifying a second target region of a SARS-CoV-2 target nucleic acid, (i) wherein the first SARS-CoV-2 region 2-specific amplification oligomer comprises a first SARS-CoV-2 region 2-specific tar

SARS-COV2 ANTIBODIES AND USES THEREOF

Absstract of: AU2023334060A1

The present disclosure is directed to antibodies and antigen binding fragments thereof, or combinations of antibodies and antigen binding fragments thereof, having binding specificity for the S protein of coronaviruses (CoV-S), such as the S protein of the SARS coronavirus 2 (SARS-CoV-2-S), including neutralizing antibodies. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. The disclosure contemplates conjugates of anti-CoV-S antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-CoV-S antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the disclosure contemplate using anti-CoV-S antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with coronaviruses or the S protein thereof and conditions where neutralization or inhibition of coronaviruses or the S protein thereof would be therapeutically beneficial.

SARS-COV-2 BINDING AGENTS AND USES THEREOF

Absstract of: WO2024050457A1

The invention relates to SARS-CoV-2 binding agents and uses thereof.

-19 METHOD AND DEVICE FOR SEPARATING COUGHING SOUNDS WITH COVID-19 CHARACTERISTICS FROM AUDIO DATA

Absstract of: KR20250101316A

코로나-19 특징을 가지는 기침 소리를 식별하는 방법 및 장치가 개시된다. 본 개시의 일 실시예에 따른, 장치에 의해 수행되는, 코로나-19 특징을 가지는 기침 소리를 식별하는 방법은, 사용자의 기침 소리가 포함된 제1 오디오 데이터를 획득하는 단계; 상기 획득된 제1 오디오 데이터에 대해 전처리를 수행하는 단계; 상기 전처리를 수행하여 획득된 상기 제1 오디오 데이터의 특징 데이터를 제1 인공지능(artificial intelligence, AI) 모델에 입력하여 상기 사용자의 기침 소리와 관련된 제2 오디오 데이터를 획득하는 단계; 상기 제2 오디오 데이터를 제2 AI 모델에 입력하여 상기 사용자의 기침 소리 및 코로나-19 감염 간의 연관도를 나타내는 최종 확률을 획득하는 단계; 및 상기 최종 확률이 제1 임계값을 초과함에 기반하여, 상기 사용자의 코로나-19 감염 가능성을 나타내는 알림 메시지를 제공하는 단계를 포함하고, 상기 제2 AI 모델은, 상기 제2 오디오 데이터로부터 추출된 기침 소리의 주파수 및 스펙트로그램(spectrogram) 이미지에 기초하여 상기 최종 확률을 출력하도록 학습되고, 상기 제1 AI 모델은, 상기 제1 AI 모델의 손실 함수 및 상기 제2 AI 모델의 손실 함수의 역전파에 기초하여 추가 학습될 수 있다.

PHARMACEUTICAL COMPOSITIONS

Absstract of: WO2025141542A1

A method of treating or reducing symptoms of coronavirus disease includes administering a therapeutically effective amount of a pharmaceutical composition to a patient, the pharmaceutical composition including an extract of Balanites aegyptiaca, wherein the pharmaceutical composition is capable of treating or reducing symptoms of coronavirus disease. Pharmaceutical compositions of the present disclosure can be used for treating or reducing symptoms of COVID-19.

ULTRAPOTENT BROARDLY NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 VARIANTS AND METHODS OF USE THEREOF

Absstract of: WO2025140539A1

Provided is in the field of immunology. Provided are broadly neutralizing antibodies against SARS-COV-2 variants, compositions and methods of prevention and treatment of SARS-COV-2 infection or transmission.

A MULTI-ANTIGENIC RNA SARS-COV-2 VACCINE AND ASSOCIATED METHODS

Absstract of: AU2023395159A1

The present technology provides multivalent vaccine compositions and Tcell compositions comprising viral antigens and associated methods. In some embodiments, the viral antigens are SARS-CoV-2 antigens. The vaccine compositions and the T cell compositions may comprise each of a Spike (S) peptide, a VME1 (M) peptide, an NCAP (N) peptide, an ORF7a (7a) peptide, an ORF3a (3a) peptide, an ORF8 (8) peptide, and an Nsp6 peptide.

Rolling Sensor Systems for Detecting Analytes and Diagnostic Methods Related Thereto

Absstract of: US2025216390A1

This disclosure relates to sensing the movement of DNA rolling motors comprising microparticles or rods on transduction material in the presence of viruses, microbes, or other analytes for diagnostic testing. In certain embodiments, the presence of viral particles, other target microbial biomolecules, or analytes stall the motor by specifically binding to aptamers crosslinking the analytes to the particles, rods, or surface of the transduction material. It is contemplated that microparticles or other rolling motors move along a surface whereby an aptamer targets an analyte, e.g., viral SARS-CoV-2, and acts to inhibit, reduce, or restrict the speed, acceleration, or area of movement on the surface indicating the presence of the analyte in the sample.

COMPOSITION COMPRISING NICOTINAMIDE, NICOTINAMIDE PRECURSORS, NICOTINAMIDE METABOLITES OR COMBINATIONS THEREOF FOR PREVENTING OR REDUCING ONE OR MORE POST-ACUTE SYMPTOMS OF INFECTIOUS DISEASES

Absstract of: US2025213549A1

A composition comprising an active substance selected from nicotinamide; nicotinic acid; nicotinic acid esters; tryptophan; a tryptophan dipeptide; nicotinamide adenine dinucleotide (NAD); nicotinamide adenine dinucleotide phosphate (NADP); an intermediate in the biosynthesis of NAD or NADP selected from the group consisting of N-formylkynurenine, L-kynurenine, 3-hydroxy-L-kynurenine, 3-hydroxyanthranilate, 2-amino-3-carboxymuconate semialdehyde, quinolinate, nicotinic acid mononucleotide (beta-nicotinate D-ribonucleotide), and nicotinic acid adenine dinucleotide; nicotinamide riboside; nicotinamide mononucleotide; 1-methylnicotinamide (N-methylnicotinamide); or a combination thereof, for use for preventing and/or reducing one or more post-acute symptoms of an infection, wherein the composition is formulated to partly or completely release the active substance(s), preferably nicotinamide, for topical supplementation or efficacy in the lower small intestine and/or the colon, wherein preferably the pathogen is SARS-CoV-2 and/or the post-acute symptoms are PCS

METHODS AND BIOAVAILABLE HIGHLY PERMEABLE COMPOUNDS FOR THE TREATMENT OF VIRAL DISEASES

Absstract of: US2025213601A1

Provided are methods and compounds for treating (or for use in manufacturing a pharmaceutical dosage form to treat) viral infections by administering avermectin-based bioavailable highly permeable compounds. The compounds, compositions, and methods provided are particularly useful for the treatment of SARS-CoV-2, dengue, chikungunya, yellow fever, Zika and other viral infections.

Engineered Probiotic Delivery System for Anti-SARS-COV-2 Treatment and Immunity Against Viruses

Absstract of: US2025213666A1

A novel genetically modified bacterium is disclosed. The bacterium has one or more anti-spike glycoprotein nanobodies on the outer membrane of the bacterium. In one embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Intimin. In another embodiment, one or more of the anti-spike glycoprotein nanobodies have been fused with Lpp-OmpA.

DOSAGE FORMS OF ACTIVE SUBSTANCES USED AGAINST VIRAL DISEASES IN DRY POWDER INHALER DEVICE FOR SYMPTOMS CAUSED BY COVID-19 AND OTHER VIRAL LUNG DISEASES

Absstract of: US2025213469A1

The present invention relates to a pharmaceutical composition in inhalable pre-metered dry powder form that comprises at least one excipient (for example carrier) and at least one active substance used against viral diseases to locally administer it to the lungs for use in the treatment of symptoms of viral lung diseases including COVID-19 caused by Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-COV-2) by means of dry powder inhaler through inhalation. The present invention also relates to methods for preparation of said pharmaceutical composition and the use of these active substances in symptoms caused by COVID-19. similar viral lung diseases, influenza.

PHARMACEUTICAL COMPOSITIONS

Absstract of: US2025213633A1

A method of treating or reducing symptoms of coronavirus disease includes administering a therapeutically effective amount of a pharmaceutical composition to a patient, the pharmaceutical composition including an extract of Balanites aegyptiaca, wherein the pharmaceutical composition is capable of treating or reducing symptoms of coronavirus disease. Pharmaceutical compositions of the present disclosure can be used for treating or reducing symptoms of COVID-19.

POLYNUCLEOTIDE VACCINES AND METHODS OF USING THE SAME

Absstract of: US2025213679A1

Disclosed herein are polynucleotides comprising a first nucleic acid encoding a first pathogen antigen and, optionally, a second nucleic acid encoding a second pathogen antigen, and, optionally, a nucleic acid encoding an immune modifier. In some aspects, the first pathogen antigen is a SARS-CoV-2 spike protein or antigenic fragment thereof. In some aspects, the second pathogen antigen is a SARS-CoV-2 protein or an antigenic fragment thereof. In some aspects, polynucletide includes two or more different immune modifiers. Also disclosed herein are vectors, compositions, pharmaceutical compositions, vaccines, lyophilized compositions, and cells comprising such polynucleotides. Methods of production and therapeutic use are also disclosed herein.

-SARS-CoV-2 Pan-SARS-CoV-2 vaccine composition

Absstract of: KR20250099656A

본 발명은 팬-SARS-CoV-2 백신 조성물 및 이의 용도에 관한 것이다. 본 발명의 팬-SARS-CoV-2 항원 및 이를 포함하는 백신 조성물은 다양한 SARS-CoV-2 변이주에 대해 우수한 백신 효능을 나타내는 바, 보다 효과가 향상된 백신을 제조할 수 있다는 장점이 있다.

SARS-COV-2 IMMUNOGENIC COMPOSITIONS AND METHODS

Absstract of: AU2023329395A1

The present disclosure relates to compositions and methods for vaccinating a subject against multiple SARS-CoV-2 variants that involves the making and delivery of extracellular vesicles expressing on their surface engineered spike protein and/or engineered nucleocapsid protein to the subject. The present invention also relates to compositions and methods for the design, preparation, manufacture, formulation, and/or use of spike-display and nucleocapsid-display vesicular vaccines designed to elicit strong humoral and cellular immune responses against multiple SARS-CoV-2 variants.

SARS-CoV-2 SARS-CoV-2 SARS-CoV-2 PEPTIDES NUCLEIC ACIDS RECOMBINANT EXPRESSION VECTORS CELLS VACCINE MATERIALS FOR SARS-COV-2 VACCINE COMPOSITIONS FOR SARS-COV-2 AND METHODS OF IMMUNIZING SARS-COV-2

Absstract of: WO2025135605A1

Disclosed are peptides, nucleic acids, recombinant expression vectors, cells, a SARS-CoV-2 vaccine substance, a SARS-CoV vaccine composition, and a SARS-CoV-2 immunization method.

NASAL SPRAY FOR USE FOR THE TREATMENT OF INFECTIONS WITH SARS-COV-2

Absstract of: PH12022550269A1

Compositions for treatment or prevention of viral infections, such as influenza A and B, coronaviruses, including but not limited to COVID-19, and rhinoviruses, along with related treatment methods. Certain compositions according to preferred embodiments of the invention may comprise chlorpheniramine, xylitol, and other inactive ingredients, such as aloe vera and / or grapefruit seed extract.

CRYSTAL FORMS OF AN ANTI-SARS COV-2 AGENT

Absstract of: MX2025003937A

The present invention features crystalline forms of Compound I, including polymorphs and pseudopolymorphs, which are useful in the preparation of pharmaceutical compositions.

2-AMINO-N-(4-AMINO-3,4-DIOXO-1-(2-OXOPYRROLIDIN-3-YL)BUTAN-2-YL)BENZAMIDE DERIVATIVES AS PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Absstract of: MX2025005933A

The present invention provides a compound of Formula I wherein R₁, R₂, R₃, R₄, R₅, R₆, R₇, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

USE OF SHENLING BAIZHU IN PREPARING MEDICAMENT FOR TREATING POST-HEALING SEQUELAE OF NOVEL CORONAVIRUS INFECTED PERSON

Absstract of: MX2025007247A

Provided is use of Shenling Baizhu in preparing a medicament for treating post-healing sequelae of a novel coronavirus infected person. The sequela is selected from at least one of short of breath, fatigue and weakness, inappetence, and diarrhea. The Shenling Baizhu is prepared from the following raw materials in parts by weight: 400 parts of ginseng, 400 parts of poria cocos, 400 parts of Rhizoma Atractylodis macrocephalae stir-fried with bran, 400 parts of Chinese yam, 300 parts of fried white hyacinth beans, 200 parts of lotus seeds, 200 parts of coix seeds stir-fried with bran, 200 parts of Fructus amomi, 200 parts of Platycodon grandiflorum, and 400 parts of liquorice.

ANTIBODIES CAPABLE OF BINDING TO THE SPIKE PROTEIN OF CORONAVIRUS SARS-COV-2

Nº publicación: SI4230650T1 30/06/2025

Applicant:

RQBIO COVID LTD [GB]
RQBio Covid Limited

Absstract of: MA61946B1

The disclosure relates to antibodies useful for the prevention, treatment and/or diagnosis of coronavirus infections, and diseases and/or complications associated with coronavirus infections, including COVID-19. In particular, the disclosure relates to antibodies capable of binding to the spike protein of coronavirus SARS-CoV-2 and uses thereof.